The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis — Worldwide, 2016–2025
China CDC Weekly · 2025 · 7 (39) · 1258-1262
DOI: 10.46234/ccdcw2025.212 ↗Kurz gefasst
Fachartikel in der Zeitschrift China CDC Weekly, 2025. Verfasst von Qingjun Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Medicine Clinical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Emergency Medicine Clinical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Infectious Disease Management Department, Chinese Center for Disease Control and Prevention, Beijing, China.
- Immunization Program, Wuhan Center for Disease Control and Prevention, Wuhan City, Hubei Province, China.
- Emergency Department/Trauma Center, Peking University People's Hospital, Beijing, China.
Zitieren
APA
Chen, Q., Yin, W., Zhu, Z., & Wang, C. (2025). The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis — Worldwide, 2016–2025. China CDC Weekly, 7(39), 1258-1262. https://doi.org/10.46234/ccdcw2025.212
Vancouver
Chen Q, Yin W, Zhu Z, Wang C. The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis — Worldwide, 2016–2025. China CDC Weekly. 2025;7(39):1258-1262. doi:10.46234/ccdcw2025.212
BibTeX
@article{Chen2025,
author = {Chen, Qingjun and Yin, Wenwu and Zhu, Zhenggang and Wang, Chuanlin},
title = {The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis — Worldwide, 2016–2025},
journal = {China CDC Weekly},
year = {2025},
volume = {7},
number = {39},
pages = {1258--1262},
doi = {10.46234/ccdcw2025.212}
}
EUVIMED